Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome
May 14, 2018 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
April 02, 2018 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
February 20, 2018 08:00 ET
|
Soleno Therapeutics
Minutes Confirm Alignment on Soleno’s Planned Phase III Clinical Trial Soleno In Process of Initiating Phase III Study REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics,...
Soleno Therapeutics Announces $15 Million Private Placement
December 12, 2017 08:30 ET
|
Soleno Therapeutics
Financing to Support Planned Phase III Clinical Program for DCCR in Prader-Willi Syndrome REDWOOD CITY, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a...
Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology
December 08, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference
November 22, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
November 14, 2017 08:00 ET
|
Soleno Therapeutics
Completed Successful EMA Meeting for DCCR in Prader-Willi SyndromeContinued Preparations to Begin Phase III ProgramPresented Positive Updated Safety and Efficacy Data from Pilot Clinical Trial of DCCR...
Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
October 23, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
October 12, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
October 11, 2017 08:00 ET
|
Soleno Therapeutics
REDWOOD CITY, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...